FindMyKOL
Clinical trialNCT03348163TerminatedPhase 4Interventional

(mo)BETTA Trial in Transwomen for Optimization of ART

NCT03348163 is a phase 4 interventional trial sponsored by The University of Texas Health Science Center, Houston. As of 21 Nov 2026, it was terminated. It studies B/FTC/TAF and Current ART in HIV Infections. The registry lists an enrollment of 26 participants at 1 site in 1 country. The registry lists a start date of 6 Jun 2018 and a primary completion date of 15 Dec 2020. One of its registered investigators has a FindMyKOL profile.

SponsorThe University of Texas Health Science Center, HoustonEnrollment26HIV Infections
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT03348163
FieldValue
Registry IDNCT03348163
StatusTerminated
PhasePhase 4
Study typeInterventional trial
Lead sponsorThe University of Texas Health Science Center, Houston
Enrollment26
Registered sites1
Countries1
ConditionsHIV Infections
DrugsB/FTC/TAF and Current ART
Start6 Jun 2018
Primary completion15 Dec 2020
Study completion15 Dec 2020
Last update posted3 Oct 2022

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to determine the safety and tolerability of a new HIV medication, bictegravir plus emtricitabine plus tenofovir alafenamide (B/FTC/TAF, 3 HIV medications combined into one pill) in HIV-infected transgender women (TW).

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Texas, United States1 site
  • Thomas Street Health Center

    Houston

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexas: 1 siteTX1FloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

B/FTC/TAFCurrent ART
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT03348163

Each answer restates registry values shown on this page.

What is NCT03348163?

NCT03348163 is a phase 4 interventional trial sponsored by The University of Texas Health Science Center, Houston. It studies B/FTC/TAF and Current ART in HIV Infections.

Who leads NCT03348163?

The registry names Jordan E Lake, MD (principal investigator, The University of Texas Health Science Center, Houston) as the overall official.

Where does NCT03348163 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT03348163 study?

The registered drug and biological interventions are B/FTC/TAF and Current ART.

When did NCT03348163 end?

The registry lists a primary completion date of 15 Dec 2020 and a study completion date of 15 Dec 2020. The sponsor last updated the record on 3 Oct 2022.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.